Nanoparticles used in medical applications for the lung: hopes for nanomedicine and fears for nanotoxicity

S Boland, R Guadagnini, A Baeza-Squiban, S Hussain and F Marano

Laboratory of Functional and Adaptive Biology, unit of Réponses Moléculaires et Cellulaires aux Xénobiotiques (RMCX), CNRS EAC 4413, University Paris Diderot-Paris 7, CC 7073, 75205 Paris Cedex 13, France.

E-mail: boland@univ-paris-diderot.fr

Abstract. Nanotechnology is a promising tool for the development of innovative treatment strategies allowing to overcome obstacles encountered by classical drug delivery. This has led to the development of nanomedicine. Indeed, nano-delivery systems (NDS) may allow the controlled release of therapeutics, protection of drugs against degradation, targeted drug delivery and facilitated transport across barriers. All these advantages of NDS are particularly interesting for treatments of the lung which is a challenging organ in respect to drug delivery. However, for the development of nanomaterials aimed to transport therapeutics, there is also a need to assess the potential health hazards of these new materials, especially as a variety of nanoparticles have been shown to induce toxicity related to their nanometer size leading to the new field of nanotoxicology. We will address both aspects of NDS, specifically in respect to lung treatments: their potential benefits and the possible adverse health effects of these materials.

1. Introduction

Nanoscience and Nanotechnology are developing very rapidly. The European Commission’s strategy for nanotechnology has highlighted the need to invest in knowledge, technology and experience in this field in Europe (COM (2004) 338). An emerging component in this field is nanomedicine which is rapidly developing. However, a comparison of the number of publications on nanomedicine with nanotechnology indicates that nanomedicine still accounts for a little amount of nanotechnology research worldwide [1]. Actually there are two areas in which the impacts of nanomedicine are likely to be most significant: first the diagnostic and medical records sector and second new treatment options [2]. Indeed, various nanoparticles (NPs) are in clinical use or under development for therapeutic purposes with the aim to develop systems for imaging and drug delivery. Nanovectors may in fact allow to overcome several challenges in drug delivery. Embedding of pharmaceuticals into nano-delivery sytems (NDS) could protect them from degradation. Furthermore a controlled release of therapeutics would enable persistent drug delivery and treatments at diminished doses. A great advantage of nanomedicine will be targeted drug delivery which allows reducing administration doses and thus lowering side-effects, toxicity and exposure of non-target organs. Certain drugs are difficult or impossible to be efficiently transported through physiological barriers and are administered systemically, which results in possible metabolism and clearance in the liver. Thus higher dosing is necessary to achieve therapeutic effects with possible target and non-target organ toxicity. An
important field of nanomedicine research is consequently the development of new treatment strategies for a controlled, selective and efficient transport of drugs through biological barriers such as the lung. However, the safety of NDS is a principal issue of concern for the development of nanomedicine as nanomaterials will interact with complex biological systems. Several in vivo and in vitro studies have indeed demonstrated that nanomaterials could induce toxicity in multiple organ systems and NDS may thus have adverse health effects which have been poorly studied thus far.

2. Promising benefits of nanovectors for improved drug delivery to the lungs

Several recent reviews have highlighted the promising role of nanomedicine for the treatment of respiratory diseases [3-5]. Indeed, the treatment of the airways could be limited by the anatomical and physiological barriers of the respiratory tract, which may be bypassed by the use of NDS. In the conducting airways, the mucociliary clearance allows the transport of foreign substances such as bacteria and particles to the pharynx, for their elimination by expectoration or ingestion. In the distal lung, the alveolar clearance is achieved by alveolar macrophages that are present in the lumen of alveoli and which are professional phagocytes. An important challenge of nanomedicine will be to circumvent these elimination roads. Furthermore, the use of NDS will allow to protect protein drugs from proteases present in the mucus and surfactant, especially in inflamed lungs. Another promising feature of NDS, beside their potential to cross the lung lining fluids, is their capacity to be taken up by respiratory epithelial cells [6] as modern treatment strategies aim to introduce expression vectors, genes, antibodies or siRNA into cells to induce or inhibit local production of proteins involved in pulmonary diseases [7-10]. As the airway epithelium is highly resistant to transfection, due to the extracellular lining fluids [11], the use of NDS is a promising tool to achieve penetration. Attempts using NDS to increase transfection efficiencies have recently been conducted for pulmonary treatments with promising results. In this regard, it is also interesting to note that endocytosis of NPs by epithelial cells has been shown to be size dependent and smaller NPs are more efficiently taken up [6,12]. The epithelium of the conducting airways also presents tight junctions, preventing paracellular crossing of foreign substances, but NPs have been shown to translocate through the epithelium in in vitro and animal studies, with smaller NPs being more efficient [13,14] thus allowing to foresee treatment strategies of the submucosa. Indeed, pathophysiological modifications, such as fibrosis and infiltration of inflammatory cells, are important features of several respiratory diseases. However, body distribution studies of inhaled NPs show low levels of translocation [15]. It is important to note that translocation studies have only been performed after a sole exposure to NPs and a more significant translocation is thus likely to occur in case of chronic exposure and coating of NPs may also allow to increase their translocation. Interestingly, long-term studies over 6 months have shown initial interstitial uptake and a return of NPs to the alveolar lumen, where they were cleared by macrophages [16]. In pathological conditions, the administration may even be more difficult. For instance, the epithelium in chronic bronchitis is characterized by mucus hypersecretion and squamous cell differentiation at late stages. Due to the hypersecretion, the delivery of drugs targeting the alveolar region may also be more difficult in COPD or asthma. Pathological situations could also increase the translocation, as shown in animal models of inflammation [17,18] which may be due to increased paracellular translocation. The differences in route of administration (inhalation versus instillation) may explain the divergence in the extent of translocation observed between studies. Instillations are generally performed at high doses as a bolus whereas inhalation studies are usually carried out at much lower doses. In vitro studies have furthermore highlighted the role of NP physicochemical characteristics in their ability to cross the epithelial barrier [19]. However, interpretation of in vitro studies has to be done with great caution since they are generally carried out at high doses. In addition, to direct translocation through the epithelial barrier, an indirect transfer via macrophages is plausible as migration of NP loaded-alveolar macrophages has been observed towards the blood circulation and extrapulmonary organs [20]. Due to the high surface area and small air-blood distance of the alveolar epithelium, the lower respiratory tract may be treated by intravenous administration of pulmonary drugs. This treatment route is already studied for antitubercular drugs and NDS have been shown to
increase their pulmonary delivery [21]. The translocation through the alveolar epithelium of drugs, by
the use of NDS, is also considered for systemic treatment strategies for non pulmonary diseases.
Insulin is already administered by inhalation (Exubera®) and NDS have been shown to increase
plasma levels [22,23]. Indeed the alveolar clearance by macrophages may be bypassed by NPs, as it
has been shown that these are less efficiently taken up by macrophages than micrometer sized particles
[13,24], whereas epithelial and interstitial uptake is increased for smaller particles [13]. Furthermore
this administration route allows circumventing first-pass metabolism and side effects seen in systemic
oral or intravenous delivery. Indeed the lung presents lower levels of drug efflux transporters and
metabolizing enzymes than the gastrointestinal tract.

Figure 1. Nanovectors for improved drug delivery to the lungs.

Nanodelivery systems (NDS) present several possibilities to improve treatments of the upper airways:
1) NDS could protect the drugs from degradation by enzymes present in the epithelial lining
 fluids.
2) The nanometre size of NDS may enable to circumvent the clearance by macrophages.
3) Facilitated crossing of the lining fluids and endocytosis of NDS will improve transfection
efficiencies. Particularly important target cells are epithelial cells, neutrophils (eg in COPD)
and eosinophils (eg in asthma).
4) Transcytosis of NDS will allow the treatment of the submucosa.
5) Crossing of the endothelium will allow systemic treatment by NDS as well as intravenous
administration of pulmonary drugs. The crossing of the air/blood barrier is however even more
prominent at the alveolar epithelium.

2.1. Benefits of NDS for innovative treatment strategies of the lung: monoclonal antibody therapies
for COPD
Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death in the
world, and if current trends continue, it is likely to rank as the third most important cause of death by
the year 2030 (WHO, World Health Statistic 2008). COPD has a well recognised inflammatory
component that is central to the development and progression of the illness and contributes also to
many of the extra-pulmonary features. As cytokines and chemokines play a critical role in the
orchestration of COPD, the use of monoclonal antibodies are valuable treatment options for more
specific therapies [8,9]. Special emphasis has been put on the inhibition of neutrophil infiltration,
which plays an important role in the pathogenesis of COPD. A multitude of antibodies targeting
cytokines, chemokines, growth factors and their receptors are considered for the treatment of COPD [8,9,25,26] and some have already been studied in clinical trials with COPD patients. The anti IL-8 antibodies Abgenix [27] improved dyspnea, but not lung function and this limited clinical benefit has been attributed to the suboptimal dosing in the airways, due to intravenous administration. Thus, the use of NDS may allow administration by inhalation, increasing local concentrations and avoiding possible side effects. Moreover, several clinical trials, with the anti TNFalpha antibody infliximab have been conducted but have shown no effects in COPD patients so far [28-30]. A clinical trial using the EGFR inhibitor BIBW 2948 in COPD patients has been conducted but was poorly tolerated. Therefore a higher local dosage is needed to allow a better inhibition of this receptor [31] and NDS should enable a better dosage at the site of action and a prolonged release of drugs. The use of monoclonal antibodies could have higher selectivity and reduced side effects compared to the use of inhibitors [9]. Thus, delivery of monoclonal antibodies such as Cetuximab (already in clinical trials for cancer therapy) could be a valuable option for the treatment of COPD.

3. Toxicity of nanomaterials
While a lot of attention has been paid to the development of new engineered nanomaterials and to new applications of nanotechnologies, comparatively less research has been performed to assess the potential hazard of these new materials. Concerns about the potential impacts of NPs on health effects have been expressed since NPs of same chemical composition possess different physicochemical properties than particles of larger size [6,13]. Indeed, when the particle size decreases, the proportion of atoms on the surface is increased to manifolds. Thus, NPs could have a greater reactivity and increased catalytic potential. This increase in the surface of engineered particles provides thus benefits compared to larger particles but could also result in much higher biological activities than bigger particles [34]. Answers to these questions are essential to identify the hazards related to nanomaterials and to accept or to compel knowingly the expected explosion of nanotechnology in general, and nanomedicine in particular. NP toxicity studies are mostly conducted with materials that are not designed for medical use (CB, CNT, metal oxides...) and which are more relevant for environmental and occupational exposures. However, in regard to development of NDS for clinical applications, the present knowledge of NP toxicity from studies on occupationally relevant NPs could be of interest. However, most of the toxicity studies have been carried out at very high doses which may not represent real-world conditions. Nevertheless these studies have allowed to identify several potential health hazards of NPs. Especially these studies have put forward the need of nanomaterial specific toxicity testing strategies and the role of physico-chemical characteristics (surface area, surface reactivity, charge as well as size and shape) in the toxicity of NPs (for review see [32]).

3.1. Pulmonary toxicity of nanomaterial
Respiratory effects of NPs are mainly inflammation, oxidative stress and functional disturbances. A variety of in vivo studies demonstrates inflammatory effects of NPs as transitory responses and assess whether the degree of the inflammatory response is related to the exposure dose of NPs. In fact, inhalation [33-35] or instillation exposures [36-38] of various types of nanomaterials have shown to induce inflammation in lungs. These studies revealed local invasion of leukocytes, increased numbers of inflammatory cells in broncho-alveolar lavage fluid (BALF), release of LDH and increased cytokine production. In addition, typical granulomatous reactions are observed after pulmonary exposures to CNTs [39-41]. Furthermore functional disturbances could be observed after NP exposure including airway hyper-reactivity (AHR) to non-specific stimuli, tissue injury leading to disturbance in respiratory functions [42-45] and effects on existing pulmonary inflammation [46]. These disturbances are generally studied in pathologic animal models, like asthma etc. Translocation could be increased by lung injury and thus the presence of cadmium NPs in the liver, after inhalation of high doses, has been attributed to their pulmonary toxicity [47]. In the context of pulmonary toxicity, it is important to note that computational models predict increased deposition of inhaled NPs in diseased or constricted
The carcinogenic potential of low toxicity low solubility dusts (LTSD), like CB and TiO$_2$, has been established in experimental animals [50] but these were generally performed at high concentrations and in sensitive species. There are very few epidemiological studies on human exposures and thus lung cancer risks could not directly be associated with engineered nanomaterials. The mechanisms leading to NP carcinogenicity are unknown and may involve primary genotoxic insult or secondary genotoxic response due to particle induced inflammation [51].

3.2. Cellular mechanisms

The cellular mechanisms, responsible for these effects, have been postulated to involve an oxidative stress induction by nanomaterials. Nel et al and Xia et al proposed a hierarchical oxidative stress model to explain the biological effect of NPs, stating that “minor levels of oxidative stress induce protective effects that may yield to more damaging effects at higher levels of oxidative stress” [52,53]. The induction of a cascade of cellular events, due to this oxidative stress, leads to the induction of redox sensitive pathways in the cells. Modifications of cell cycle, proliferation, pro-inflammatory response and cell death by apoptosis or necrosis could be the consequences. Many recent reviews on the mechanisms of action of NPs sustain this oxidative stress paradigm [52-54] while few have questioned the central role of oxidative stress in these responses to NP [55,56]. Several studies pointed out the roles of size and surface reactivity in the ability to induce an oxidative stress [33,53]. The adverse effects on the target tissues could either be due to abiotic or biotic reactive oxygen species (ROS) induced by NP or to ROS produced indirectly from the inflammatory process induced by NP exposures. The activation of redox sensitive transcription factors, such as NF-kappaB, AP1 or Nrf2, by this oxidative stress could lead to the transcription of a number of pro-inflammatory genes and the increased release of numerous pro-inflammatory factors. However, adaptive responses may diminish these effects which make the extrapolation on health effects in humans very difficult.

A modulation of intracellular calcium by carbon black NPs has also been demonstrated [57]. This transient increase of intracellular calcium by NPs has been shown to trigger impaired phagosome transport and cytoskeletal dysfunctions. The underlying mechanism may involve direct effects of NPs on ion channels which control the cellular calcium homeostasis. Higher NP concentrations have also been shown to induce apoptosis in a variety of cells [58-62]. Differential signalling events are responsible for these apoptotic effects, involving death receptor, mitochondria or lysosomes.

4. Conclusions

Nanomedicine presents a great opportunity for the radical improvement of current therapies and development of new treatment options for diseases previously thought difficult or impossible to treat. In particular the treatment of lung disorders could be achieved by the use of specially designed NDS. In this paper we reviewed the multiple advantages of NDS to improve lung treatments, particularly the special feature of NPs to be taken up by cells and to translocate through the epithelial barrier. However, the need exists of a balance between therapeutic efficacy and safety of the NDS with the aim to increase the benefit to risk ratio. Studies of pulmonary toxicity of environmental and occupational NPs allow to foresee possible adverse health effects of NDS. There is now a great need to perform studies with chronic exposures at low doses which are more realistic to be encountered in real live conditions. The understanding of the mechanisms behind these NP specific effects is essential for the development of safe NDS allowing the rapid expansion of new applications of nanomedicine for innovative treatment strategies.

Acknowledgement

Supported by EC FP7 (Health-2007-1.3-4) Contract no: 201335
References
[1] Wagner V, Dullaart A, Bock AK, and Zweck A. 2006 The emerging nanomedicine landscape. Nature Biotechnology 24 Number 10 October 1211-17.
[2] Allhoff F. The Coming Era of Nanomedicine The American Journal of Bioethics, 9(10) 3–11.
[3] Card JW, Zeldin DC, Bonner JC, Nestmann ER. 2008 Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol. 295(3) L400-11.
[4] Smola M, Vandamme T, Sokolowski A. 2008 Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int J Nanomedicine 3(1) 1-19.
[5] Mansour HM, Rhee YS, Wu X. 2009 Nanomedicine in pulmonary delivery. Int J Nanomedicine 4 299-319
[6] Hussain S, Boland S, Baeza-Squiban A, Hamel R, Thomassen LC, Martens JA, Billon-Galland MA, Fleury-Feith J, Moisan F, Païron JC, Marano F. 2009 Oxidative stress and proinflammatory effects of carbon black and titanium dioxide nanoparticles: role of particle surface area and internalized amount. Toxicology 16;260(1-3):142-9.
[7] Tanaka M, Nyce JW. 2001 Respirable antisense oligonucleotides: a new drug class for respiratory disease. Respir Res. 2(1) 5-9.
[8] Yamagata T, Ichinose M. Agents against cytokine synthesis or receptors. 2006 Eur J Pharmacol 8;533(1-3):289-301.
[9] Li L, Das AM, Torphy TJ, Griswold DE. 2002 What’s in the pipeline? Prospects for monoclonal antibodies (mAbs) as therapies for lung diseases. Pulm Pharmacol Ther 15(5) 409-16.
[10] Gill DR, Bazzani RP, Hyde SC. 2010 Strategies for long-term expression of transgenes in the respiratory epithelium. Curr Opin Mol Ther 12(4) 386-93
[11] Sanders N, Rudolph C, Braeckmans K, De Smedt SC, Demeester J. 2009 Extracellular barriers in respiratory gene therapy. Adv Drug Deliv Rev. 27:61(2):115-27
[12] Limbach LK, Wick P, Manser P, Grass RN, Bruinink A and Stark WJ. 2007 Exposure of engineered nanoparticles to human lung epithelial cells: influence of chemical composition and catalytic activity on oxidative stress. Environ. Sci. Technol. 41 4158–63.
[13] Oberdörster G, Oberdörster E, Oberdörster J. 2005 Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 113(7) 823-39.
[14] Semmler-Behnke M, Kreyling W, Lipka J, Fertsch S, Wenk A, Takenaka S, Schmid G, Brandau W. 2008 Biodistribution of 1.4- and 18-nm gold particles in rats. Small 4(12) 2108-11.
[15] Kreyling W, Semmler-M, Erbe F, Mayer P, Takenaka S, Schulz H, Oberdörster G, Ziesenis A. 2002 Translocation of ultrafine insoluble iridium particles from lung epithelium to extrapulmonary organs is size dependent but very low. J Toxicol Environ Health A 65(20) 1513-30.
[16] Semmler-Behnke M, Takenaka S, Fertsch S, Wenk A, Seitz J, Mayer P, Oberdörster G, Kreyling W. 2007 Efficient elimination of inhaled nanoparticles from the alveolar region: evidence for interstitial uptake and subsequent reentrainment onto airways epithelium. Environ Health Perspect 115(5) 728-33.
[17] Chen J, Tan M, Nemmar A, Song W, Dong M, Zhang G, Li Y. 2006 Quantification of extrapulmonary translocation of intratracheal-instilled particles in vivo in rats: effect of lipopolysaccharide. Toxicology 222(3) 195-201.
[18] Meiring J, Borm P, Bagate K, Semmler M, Seitz J, Takenaka S, Kreyling W. 2005 The influence of hydrogen peroxide and histamine on lung permeability and translocation of iridium nanoparticles in the isolated perfused rat lung. Part Fibre Toxicol 2 3
[19] Yacobi N, Demaio L, Xie J, Hamm-Alvarez S, Borok Z, Kim K, Crandall E. 2008 Polystyrene nanoparticle trafficking across alveolar epithelium. Nanomedicine 4(2) 139-45.
[20] Furuyama A, Kanno S, Kobayashi T, Hirano S. 2009. Extrapulmonary translocation of intratracheally instilled fine and ultrafine particles via direct and alveolar macrophage-
associated routes. *Arch Toxicol* **83**(5) 429-37

[21] Pandey R, Zahoor A, Sharma S, Khuller GK. 2003 Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. *Tuberculosis (Edinb)* **83**(6) 373-8

[22] Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T. 1999 Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. *J Control Release* **1**;62(1-2):279-87

[23] Zhang Q, Shen Z, Nagai T. 2001 Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. *Int J Pharm* **7**;218(1-2):75-80

[24] Geiser M, Casaulta M, Kupferschmid B, Schulz H, Semmler-Behnke M, Kreyling W. 2008 The role of macrophages in the clearance of inhaled ultrafine titanium dioxide particles. *Am J Respir Cell Mol Biol* **38**(3) 371-6.

[25] Church LD, McDermott MF. 2009 Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. *Curr Opin Mol Ther* **1**;11(1) 81-9

[26] Barnes PJ. 2003 Cytokine-directed therapies for the treatment of chronic airway diseases. *Cytokine Growth Factor Rev* **1**;14(6) 511-22

[27] Mahler DA, Huang S, Tabrizi M, Bell GM. 2004 Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. *Chest* **1**;126(3) 926-34.

[28] Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenbrot P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohue JF, Watt R, Lo KH, Schlenker-Herceg R, Barnathan ES, Murray J. 2007 The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* **1**;175(9):926-34

[29] Dentener MA, Creutzberg EC, Pennings HJ, Rijkers GT, Mercken E, Wouters EF. 2008 Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. *Respiration* **7**;65(3) 275-82.

[30] Van der Vaart H, Koëter GH, Postma DS, Kauffman HF, ten Hacken NH. 2005 First study of infliximab treatment in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* **1**;171(9):926-34

[31] Woodruff PG, Wolff M, Hohlfeld JM, Krug N, Dransfield MT, Sutherland ER, Criner GJ, Kim V, Prasse A, Nivens MC, Tetzlaff K, Heilker R, Fahy JV. 2010 Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* **1**;181(5):438-45.

[32] Baeza A, Boland S, Hussain S, Marano F. 2011 Health effects of nanoparticles. *Systems Toxicology : from omics technology to nanotechnology » John Wiley and Sons Ltd.*

[33] Bermudez E, Mangum JB, Wong BA, Asgharian B, Hext PM, Warheit DB, Everett JI. 2004. Pulmonary responses of mice, rats, and hamsters to subchronical inhalation of ultrafine titanium dioxide particles. *Toxicol.Sci.* **7**;77(2) 347-357.

[34] Elder A, Gelein R, Finkelstein JN, Driscoll KE, Harkema J, Ober dorster G. 2005 Effects of subchronically inhaled carbon black in three species. I. Retention kinetics, lung inflammation, and histopathology. *Toxicol.Sci.* **8**;88(2) 614-629.

[35] Grassian VH, O'Shaughnessy PT, Mckova-Dodd A, Pettibone JM, Thorne PS. 2007. Inhalation exposure study of titanium dioxide nanoparticles with a primary particle size of 2 to 5 nm. *Environ.Health Perspect.* **1**;115(3) 397-402.

[36] Warheit DB, Webb TR, Reed KL. 2006. Pulmonary toxicity screening studies in male rats with TiO2 particulates substantially encapsulated with pyrogenically deposited, amorphous silica. *Part Fibre Toxicol.* **3** 3.

[37] Warheit DB, Webb TR, Reed KL, Frerichs S, Sayes CM. 2007. Pulmonary toxicity study in rats with three forms of ultrafine-TiO2 particles: differential responses related to surface properties. *Toxicology* **2**30(1) 90-104.
[38] Warheit DB, Webb TR, Sayes CM, Colvin VL, Reed KL. 2006b. Pulmonary instillation studies with nanoscale TiO2 rods and dots in rats: toxicity is not dependent upon particle size and surface area. *Toxicol. Sci.* 91(1) 227-236.

[39] Lam CW, James JT, McCluskey R, Hunter RL. 2004. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. *Toxicol. Sci.* 77(1) 126-134.

[40] Mercer RR, Scabilloni J, Wang L, Kisin E, Murray AR, Schwegler-Berry D, Shvedova AA, Castranova V. 2008. Alteration of deposition pattern and pulmonary response as a result of improved dispersion of aspirated single-walled carbon nanotubes in a mouse model. *Am. J. Physiol Lung Cell Mol. Physiol* 294(1) L87-L97.

[41] Warheit DB, Laurence BR, Reed KL, Roach DH, Reynolds GA, Webb TR. 2004. Comparative pulmonary toxicity assessment of single-wall carbon nanotubes in rats. *Toxicol. Sci.* 77(1) 117-125.

[42] Alessandrini F, Schulz H, Takenaka S, Lentner B, Karg E, Behrendt H, Jakob T. 2006. Effects of ultrafine carbon particle inhalation on allergic inflammation of the lung. *J. Allergy Clin. Immunol.* 117(4) 824-830.

[43] Inoue K, Takano H, Yanagisawa R, Koike E, Shimada A. 2009. Size effects of latex nanomaterials on lung inflammation in mice. *Toxicol. Appl. Pharmacol.* 234(1) 62-68.

[44] Inoue K, Takano H, Yanagisawa R, Sakurai M, Abe S, Yoshino S, Yamaki K, Yoshikawa T. 2007. Effects of nanoparticles on lung physiology in the presence or absence of antigen. *Int. J. Immunopathol. Pharmacol.* 20(4) 737-744.

[45] Hussain S, Vanoirbeek JA, Luyts K, De Vooght V, Verbeken E, Thomassen LC, Martens JA, Dinsdale D, Boland S, Marano F, Nemery B, Hoet PH. 2010. Lung exposure to nanoparticles modulates an asthmatic response in a mouse model of asthma. *Eur Respir J.* 611.

[46] Nygaard UC, Samuelsen M, Aase A, Lovik M. 2004. The capacity of particles to increase allergic sensitization is predicted by particle number and surface area, not by particle mass. *Toxicol. Sci.* 82(2) 515-524.

[47] Takenaka S, Karg E, Kreiling WG, Lentner B, Schulz H, Ziesenis A, Schramel P, Heyder J. 2004. Fate and toxic effects of inhaled ultrafine cadmium oxide particles in the rat lung. *Inhal Toxicol.* 16 Suppl 1:83-92.

[48] Farkas A, Balásházy I, Szocs K. 2006. Characterization of regional and local deposition of inhaled aerosol drugs in the respiratory system by computational fluid and particle dynamics methods. *J Aerosol Med.* 19(3) 329-43.

[49] Anderson PJ, Wilson JD, Hiller FC. 1990. Respiratory tract deposition of ultrafine particles in subjects with obstructive or restrictive lung disease. *Chest.* 97(5) 1115-20.

[50] Roller M. 2009. Carcinogenicity of inhaled nanoparticles. *Inhal. Toxicol.* 21(S1) 144-157.

[51] Schins RP, Knaapen AM. 2007. Genotoxicity of poorly soluble particles. *Inhal. Toxicol.* 19 Suppl 1:189-198.

[52] Nel A, Xia T, Mädler L, Li N. 2006. Toxic potential of materials at the nanolevel. *Science* 311(5761) 622-7.

[53] Xia T, Kovochich M, Brant J, Hotze M, Sempf J, Oberley T, Sioutas C, Yeh J, Wiesner M, Nel A. 2006. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. *Nano Lett.* 6(8) 1794-807.

[54] Hoet P, Nemmar A, Nemery B. 2004. Health impact of nanomaterials? *Nat Biotechnol* 22(1):19.

[55] Donaldson K, Borm PJ, Castranova V, Gulumian M. 2009. The limits of testing particle-mediated oxidative stress in vitro in predicting diverse pathologies; relevance for testing of nanoparticles. *Part Fibre Toxicol.* 27:6:13.

[56] Marano F, Hussain S, Rodrigues-Lima F, Baeza-Squiban A, Boland S. 2010. Nanoparticles: molecular targets and cell signalling. *Arch Toxicol.* 526.

[57] Möller W, Brown D, Kreyling W, Stone V. 2005. Ultrafine particles cause cytoskeletal dysfunctions in macrophages: role of intracellular calcium. *Part Fibre Toxicol.* 2:7.

[58] Pan Y, Leifert A, Ruau D, Neuss S, Bornemann J, Schmid G, Brandau W, Simon U, Jahnen-
Dechent W. 2009. Gold nanoparticles of diameter 1.4 nm trigger necrosis by oxidative stress and mitochondrial damage. *Small* 5(18) 2067-76.

[59] Pan Y, Neuss S, Leifert A, Fischler M, Wen F, Simon U, Schmid G, Brandau W, Jahnendechent W. 2007. Size-dependent cytotoxicity of gold nanoparticles. *Small* 3(11) 1941-9.

[60] Sydlik U, Bierhals K, Soufi M, Abel J, Schins R, Unfried K. 2006. Ultrafine carbon particles induce apoptosis and proliferation in rat lung epithelial cells via specific signaling pathways both using EGF-R. *Am J Physiol Lung Cell Mol Physiol* 291(4) L725-33.

[61] Vamanu C, Cimpan M, Høl P, Sørnes S, Lie S, Gjerdet N. 2008. Induction of cell death by TiO2 nanoparticles: studies on a human monoblastoid cell line. *Toxicol In Vitro* 22(7) 1689-96.

[62] Hussain S, Thomassen LC, Ferecatu I, Borot MC, Andreau K, Martens JA, Fleury J, Baeza-Squiban A, Marano F, Boland S. 2010. Carbon black and titanium dioxide nanoparticles elicit distinct apoptotic pathways in bronchial epithelial cells. *Part Fibre Toxicol*. 16;7:10.